



## **CERTIFICATE OF ANALYSIS**

### **Purified AAV9-CMV-GFP (Lot 19-316)**

(for research use only)

### **Storage Conditions**

The AAV vectors should be stored at  $-80^{\circ}\text{C}$  for long term usage. When storing for frequent use,  $4^{\circ}\text{C}$  is recommended. Avoid storing at  $-20^{\circ}\text{C}$ . The plasmid should be stored at  $-20^{\circ}\text{C}$  for long term usage.

### **Shelf Life**

4 years when stored at  $-80^{\circ}\text{C}$ . (AAV)

### **Shipping Conditions**

Wet Ice Overnight

### **Description**

AAV9-CMV-GFP was produced in insect Sf9 cells by infection with rBV-inCap9-inRepCap-kozak-hr2 (V289) (Fig 2) and rBV-CMV-GFP (V445) (Fig 3).

The vectors were purified through 2 rounds of CsCl ultracentrifugations. The CsCl was removed through buffer exchange with 2 PD-10 desalting columns. The final AAVs are in 1xPBS+0.001% pluronic F-68 buffer.

The vectors are for research use only, not for any human use.

### **qPCR Titer**

Lot 19-316:  $2\text{E}+13$  vg/ mL (final diluted)



### Quality Control Data

The vectors were sterilized with 0.22 $\mu$ m filter. SDS-PAGE and InstantBlue Staining (Expedeon) verified the purity of the vectors (Fig. 1). Real-time PCR analysis determined the titers of the AAV samples.




Fig. 1. SDS-PAGE and InstantBlue Staining of purified AAV9-CMV-GFP (Lot: 19-316).



Plasmids map




Fig. 2. Diagram of plasmid used to generate rBV- inCap9-inRepCap-kozak-hr2 (V289).





Fig. 3. Diagram of plasmid used to generate rBV- CMV-GFP (V445).

Approved by:  Thursday, October 21, 2021